Recombinant Human Tenascin (TNC), Truncated

The preparation of this recombinant Human TNC protein was to use gene recombination DNA technology to obtain a recombinant vector connected with a TNC fragment (1888-2201aa) that could be translated into the TNC protein and then transferred it into E.coli cells to express the recombinant TNC protein molecule. In order to get the target protein with high purity, N-terminal 6xHis tag was used in the production. The purity is 90% determined by SDS-PAGE.Tenascin is an extracellular matrix protein with a spatially and temporally restricted tissue distribution. This protein is homohexameric with disulfide-linked subunits, and contains multiple EGF-like and fibronectin type-III domains. TNC level is undetectable in most adult tissues but rapidly and transiently induced by a handful of pro-inflammatory cytokines in a variety of pathological conditions including infection, inflammation, fibrosis, and wound healing. The increased deposition of TNC has been reported in the tumor stroma of most epithelial malignancies arising, for example, in the breast, uterus (both the cervix and body), ovary, prostate, pancreas, colon, stomach, mouth, larynx, lung, urinary tract, and skin. Interactions between epithelial (cancer) and stroma cells induce the expression of TNC by both cells, thereby facilitating the remodeling of cancer tissues. Deposited TNC in the cancer stroma modulates the cell behaviors of both cell types by interactions between cells and ECM that are mediated through integrins.